Current Report Filing (8-k)
March 03 2020 - 12:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March
3, 2020
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
|
Delaware
|
|
001-37526
|
|
26-0389433
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrant’s Telephone Number, Including
Area Code)
Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
|
|
¨
|
Pre–commencement
communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
|
|
¨
|
Pre–commencement
communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, $0.001 par value per share
|
|
ZYNE
|
|
The NASDAQ Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. x
On March 3, 2020 Zynerba Pharmaceuticals, Inc. (the “Company”)
issued a press release announcing that it is presenting a two posters at the American Society for Experimental Neurotherapeutics
2020 Meeting in Bethesda, MD (ASENT 2020 Meeting). The posters relating to the health burden and diagnostic challenges of Fragile
X syndrome (FXS) are entitled “Post Hoc Analysis - An Open-Label Study of Transdermal Cannabidiol (ZYN002) for the Treatment
of Fragile X Syndrome in Children and Adolescents: Estimating Health State Utility Scores” and “Fragile X Syndrome
Diagnosis and Patient Journey: The Caregiver’s Perspective”.
On March 3, 2020, the Company issued a second press release
announcing that is presenting a third poster at the ASENT 2020 Meeting describing the baseline characteristics of the pediatric
and adolescent patients in the Company’s Phase 2 BRIGHT trial entitled “Phase 2 BRIGHT (An Exploratory Open-Label
Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents
with Autism Spectrum Disorder) Trial: Baseline Characteristics.”
Copies of these press releases are attached
hereto as Exhibits 99.1 and 99.2 and incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
The following exhibits are being filed herewith:
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 3, 2020
|
|
ZYNERBA PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Suzanne Hanlon
|
|
|
|
Name: Suzanne Hanlon
|
|
|
|
Title: Secretary, Vice President and General Counsel
|
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2023 to Apr 2024
